Takeda cuts 2 midstage GI assets including Crohn's hopeful in latest pipeline cleanup

Takeda cuts 2 midstage GI assets including Crohn's hopeful in latest pipeline cleanup

Source: 
Fierce Biotech
snippet: 

Takeda may have caught attention recently for ending work on its early-stage gene therapy R&D, but a close reading of the Japanese pharma’s latest earnings report reveals it has also culled a couple of gastrointestinal assets.